Results 101 to 110 of about 28,766 (211)
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source
Merkel cell polyomavirus and Merkel cell carcinoma
A new polyomavirus, Merkel cell polyomavirus, was identified from Merkel cell carcinoma, a rare skin cancer. Origin of Merkel cell carcinoma is Merkel cell, a neuroendocrine cell in the skin. Merkel cell carcinoma occurs in the skin of head and face of white elders.
Tomoyuki, Nakamura, Harutaka, Katano
openaire +3 more sources
Will the Dermatoscopic Characterization of Merkel Cell Carcinoma Remain an Enigma?
International Journal of Dermatology, EarlyView.
Cliff Rosendahl, Alan Cameron
wiley +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Summary Background In cutaneous squamous cell carcinoma (cSCC), there is a paucity of data regarding local recurrence (LR) and regional lymph node metastasis (LM) as precursors to tumor death. Patients and Methods We estimated parameters of a multistate model with a proportion of patients without risk of progression using maximum likelihood.
Helmut Breuninger +3 more
wiley +1 more source
Summary Defensive medicine refers to diagnostic or therapeutic actions taken primarily to reduce legal liability rather than to benefit the patient. In dermatopathology, defensive practices manifest in frequent immunohistochemical testing, overly cautious report phrasing, and reliance on multidisciplinary tumor boards.
Cornelia Sigrid Lissi Müller +2 more
wiley +1 more source
ABSTRACT Cancer cells rely on citrate for multiple metabolic processes, suggesting that limiting the availability of extracellular citrate may represent a novel therapeutic strategy. The plasma membrane citrate transporter (pmCiC) has been implicated in the pathogenesis of several cancers before, and its activity can be inhibited by gluconate.
Konstantin Drexler +8 more
wiley +1 more source
Merkel cell carcinoma - particularities and morphological aspect of a unique and rare entity
Introduction: Merkel cell carcinoma is a very rare malignant neoplasm which presents high aggressivity, high recurrence rate and has meta-static potential.
Tinca Andreea Cătălina +2 more
doaj +1 more source
Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next
The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal +3 more
wiley +1 more source
Rak neuroendokrynny skóry (Merkla) – aktualne poglądy na patogenezę oraz metody leczenia
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skincancer localized mostly on exposed, sun-damaged skin – on the headand neck. Although rapidly increasing incidence of MCC is observed,the pathogenesis of the tumour is unclear. Diagnosis
Beata Sosada, Ligia Brzezińska-Wcisło
doaj

